Literature DB >> 29789416

Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.

Valeria Quaranta1, Carolyn Rainer1, Sebastian R Nielsen1, Meirion L Raymant1, Muhammad S Ahmed1, Dannielle D Engle2, Arthur Taylor3, Trish Murray3, Fiona Campbell1, Daniel H Palmer1, David A Tuveson2,4, Ainhoa Mielgo1, Michael C Schmid5.   

Abstract

The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumor microenvironment that suppresses and excludes cytotoxic CD8+ T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not completely understood. In this study, we find that macrophage-derived granulin contributes to cytotoxic CD8+ T-cell exclusion in metastatic livers. Granulin expression by macrophages was induced in response to colony-stimulating factor 1. Genetic depletion of granulin reduced the formation of a fibrotic stroma, thereby allowing T-cell entry at the metastatic site. Although metastatic PDAC tumors are largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin-depleted tumors restored the antitumor immune defense and dramatically decreased metastatic tumor burden. These findings suggest that targeting granulin may serve as a potential therapeutic strategy to restore CD8+ T-cell infiltration in metastatic PDAC, thereby converting PDAC metastatic tumors, which are refractory to immune checkpoint inhibitors, into tumors that respond to immune checkpoint inhibition therapies.Significance: These findings uncover a mechanism by which metastatic PDAC tumors evade the immune response and provide the rationale for targeting granulin in combination with immune checkpoint inhibitors for the treatment of metastatic PDAC.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4253/F1.large.jpg Cancer Res; 78(15); 4253-69. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29789416      PMCID: PMC6076440          DOI: 10.1158/0008-5472.CAN-17-3876

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 2.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

3.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Authors:  Vinod P Balachandran; Marta Łuksza; Julia N Zhao; Vladimir Makarov; John Alec Moral; Romain Remark; Brian Herbst; Gokce Askan; Umesh Bhanot; Yasin Senbabaoglu; Daniel K Wells; Charles Ian Ormsby Cary; Olivera Grbovic-Huezo; Marc Attiyeh; Benjamin Medina; Jennifer Zhang; Jennifer Loo; Joseph Saglimbeni; Mohsen Abu-Akeel; Roberta Zappasodi; Nadeem Riaz; Martin Smoragiewicz; Z Larkin Kelley; Olca Basturk; Mithat Gönen; Arnold J Levine; Peter J Allen; Douglas T Fearon; Miriam Merad; Sacha Gnjatic; Christine A Iacobuzio-Donahue; Jedd D Wolchok; Ronald P DeMatteo; Timothy A Chan; Benjamin D Greenbaum; Taha Merghoub; Steven D Leach
Journal:  Nature       Date:  2017-11-08       Impact factor: 49.962

4.  Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

Authors:  Andrea Casazza; Damya Laoui; Mathias Wenes; Sabrina Rizzolio; Nicklas Bassani; Marco Mambretti; Sofie Deschoemaeker; Jo A Van Ginderachter; Luca Tamagnone; Massimiliano Mazzone
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 5.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 6.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

7.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

8.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701

9.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

View more
  44 in total

1.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

2.  Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages.

Authors:  Marcos Andre Rodrigues da Costa Santos; Jhenifer Santos Dos Reis; Carlos Antonio do Nascimento Santos; Kelli Monteiro da Costa; Pedro Marçal Barcelos; Karen Queiroz de Oliveira Francisco; Pedro Antônio Guimarães Notaroberto Barbosa; Emanuelle Damasceno Souza da Silva; Celio Geraldo Freire-de-Lima; Alexandre Morrot; Debora Decote-Ricardo; Israel Diniz-Lima; Jose Osvaldo Previato; Lucia Mendonca-Previato; Leonardo Marques da Fonseca; Leonardo Freire-de-Lima
Journal:  Immunol Res       Date:  2022-10-05       Impact factor: 4.505

Review 3.  Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.

Authors:  Rosalia Busà; Matteo Bulati; Ester Badami; Giovanni Zito; Daniela Claudia Maresca; Pier Giulio Conaldi; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Cell Dev Biol       Date:  2022-05-26

Review 4.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

5.  Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.

Authors:  Chirag Krishna; Renzo G DiNatale; Fengshen Kuo; Raghvendra M Srivastava; Lynda Vuong; Diego Chowell; Sounak Gupta; Chad Vanderbilt; Tanaya A Purohit; Ming Liu; Emily Kansler; Briana G Nixon; Ying-Bei Chen; Vladimir Makarov; Kyle A Blum; Kyrollis Attalla; Stanley Weng; Michael L Salmans; Mahdi Golkaram; Li Liu; Shile Zhang; Raakhee Vijayaraghavan; Traci Pawlowski; Victor Reuter; Maria I Carlo; Martin H Voss; Jonathan Coleman; Paul Russo; Robert J Motzer; Ming O Li; Christina S Leslie; Timothy A Chan; A Ari Hakimi
Journal:  Cancer Cell       Date:  2021-04-15       Impact factor: 31.743

Review 6.  Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.

Authors:  Samarth Hegde
Journal:  Indian J Surg Oncol       Date:  2020-08-25

Review 7.  Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.

Authors:  Mehdi Chaib; Subhash C Chauhan; Liza Makowski
Journal:  Front Cell Dev Biol       Date:  2020-05-19

Review 8.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 9.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 10.  Liver Tropism in Cancer: The Hepatic Metastatic Niche.

Authors:  Ainhoa Mielgo; Michael C Schmid
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.